Search This Blog

Monday, February 2, 2026

Why NYC teachers are sour on Hochul and Mamdani’s plans to expand child care

 Child care in New York City has been in crisis for decades.

Ten years ago, City Hall launched universal pre-K for 4-year-olds to help ease parents’ high child-care costs.

Five years later, 3-K for 3-year-olds aimed to do the same.

Now, with the crisis persisting, Gov. Kathy Hochul and Mayor Zohran Mamdani last month announced plans to expand those programs further with free child care for all 2-year-olds by 2030, with the rollout beginning this year.

Parents were excited. 

Parents were lied to. 

It’s not going to happen — because building on the existing system is a recipe for disaster.

The city’s cramped public schools lack the space to house its current preschool programs, and mandatory class-size caps mean they’ll soon have even fewer classrooms available for younger children.

That’s why 60% of today’s enrolled tots attend pre-K and 3-K classes run by Community Based Organizations.

The program for 2-year-olds would have to piggyback on the CBO system — and that system is already stretched to the breaking point

“When you expand programs without stabilizing the ones already in place,” special-education expert Joy Farina Foskett told me, “you’re asking programs to fail.”

The biggest issue is a critical teacher shortage, driven largely by disparities in teacher pay.

The starting salary for a new public-school teacher with a bachelor’s degree and no experience is $71,314  — while a new teacher in a CBO can earn as little as $34,991 to start, the city comptroller’s office reported.

That drives high teacher turnover, which is extraordinarily harmful to the youngest children.

For little ones, “stable relationships with caregivers are foundational to learning, emotional regulation and a sense of safety,” Foskett said.

“High teacher turnover is not just a workforce issue; it is a child development issue.”

The caregiver revolving door “has real measurable consequences, such as disrupted attachments,” agreed Lori Cangiolose of Staten Island’s The Playgroup Experience.

“Stability is fundamental at this age, and turnover disturbs that,” she said. “Families have to repeatedly build relationships and trust with new teachers.”

Another major issue: Expanding the city’s child-care system will mean enrolling more preschoolers with special needs.

Already, said Foskett, “CBOs are increasingly serving children who require inclusive, developmentally responsive support, yet often go without sufficient staffing [or] specialized services.”

“We had one child who would throw materials, push furniture and scream,” recalled Rebecca Schneider-Kaplan of The Children’s Center in Staten Island. “The other students were very upset when this would happen.”

In the class of 18 3-year-olds, led by a team of one teacher and one assistant, “we didn’t have enough teachers to manage the situation,” she confessed.

“We are very concerned that in case of an emergency, it would be difficult to manage that many children with just two people.”

Another concern in an emergency situation is the lack of on-site security.

“Most CBOs do not have security of any kind, and none of them have school safety agents,” said Chloe Pashman, a school director in The Bronx.

“We’ve had a parent mugged in broad daylight in front of the school while he was holding his pre-K child, strange people hanging around the playground attached to our school, and people physically fighting out front,” she said.

On top of all these issues, Hochul’s bare-bones 2Care proposal suggests that the expansion would rely in large part on family child-care providers who already run day-care businesses from their homes. 

When the city launched universal pre-K and 3-K, private preschools were “forced to join the city’s program or [would] be forced to close our doors,” one director told me in confidence.

But “the funding and support have never matched expectations placed on programs, educators and owners.”

Will that be true for the city’s thousands of small family providers as well — and will they too be subject to bargain-basement wages and deficient security?

Pashman thinks that’s exactly what would happen.

“Most of our staff is not white, and the majority are women,” she noted. “The city has gotten away with loading 3-K and pre-K on the backs of these women — why wouldn’t they try it with 2-year-olds? It’s a great deal for them. They get us all on the cheap.”

It’s easy to see why parents are excited by the Hochul-Mamdani promise of free child care in a city with a sky-high cost of living. 

But as a working parent myself, I can’t stomach the thought of that benefit coming at such a price.

“Against this backdrop, proposals to expand programming such as 2-K or infant and toddler care raise serious concerns,” Foskett said. “Expansion without reform risks weakening the very system NYC depends on.”

Reform must come first.

Alina Adams is the author of “Getting into NYC Kindergarten” and the producer of NYCSchoolSecrets.com.

https://nypost.com/2026/02/01/opinion/why-nyc-teachers-are-sour-on-hochul-and-mamdanis-plans-to-expand-child-care/

Huge Surge In New Orders Sends US Manufacturing Activity Near 4 Year Highs

 With 'hard' data sustaining signs of solid growth (e.g. factory orders and jobless claims), 'soft' survey data has been bouncing back since the start of the year

This morning we get the final Manufacturing PMI data from S&P Global and ISM for January.

A solid and stronger improvement in US manufacturing sector operating conditions (52.4 vs 52.0 exp) was signaled by January’s S&P Global PMI data amid the joint-sharpest upturn in production since May 2022.

However, growth was in part driven by inventory building as new orders, despite returning to expansion in January, increased only modestly.

ISM's Manufacturing was expected to rise from 47.9 to 48.5 in January but instead it soared to 52.6 - its highest since Aug 2022. This is the first print above 50 since January 2025.

Source: Bloomberg

This was the biggest MoM surge in the ISM print since April 2020 (COVID rebound), led by a huge surge in new orders and rise in employment (highest in a year) and prices (though elevated) are stable...

“News of the joint largest rise in factory production since May 2022 is tainted by reports of ongoing subdued sales growth," says Chris Williamson, Chief Business Economist at S&P Global Market Intelligence.

"Production growth consequently significantly outpaced that of new orders at the start of the year, resulting in a further accumulation of unsold warehouse inventory."

Over the past three months, the survey indicates that factories have typically produced more goods than they have sold to a degree we have not previously seen since the global financial crisis back in early 2009."

This highly unusual situation is clearly unsustainable, hinting at risks of a production slowdown and a potential knock-on effect on employment, unless demand improves markedly in the coming months.

Williamson adds that “sluggish sales and order book growth are being commonly linked to customer resistance to high prices, in turn often blamed on tariffs, as well as increased uncertainty over the economic outlook."

While just below trend, business growth expectations for the year ahead are, however, holding up as firms anticipate improving demand, "thanks in part to lower interest rates, reduced import competition due to tariffs, and more government support."

However, as Williamson concludes, "political uncertainty remains a key drag on business sentiment."

https://www.zerohedge.com/economics/huge-surge-new-orders-sends-us-manufacturing-activity-near-4-year-highs

Trump Launches $12 Billion Strategic Mineral Stockpile To Counter China; Rare Earth Stocks Jump

 The Trump administration is preparing to launch a major initiative aimed at protecting US manufacturers from disruptions in the supply of critical minerals, committing about $12 billion in initial funding to build a strategic stockpile of essential materials, according to Bloomberg. The project, known as Project Vault, is designed to reduce America’s dependence on China for rare earths and other strategically important metals. By creating a centralized reserve for civilian industries, officials hope to cushion companies against sudden shortages and sharp price swings that can disrupt production and strain finances.

Shares of MP Materials, USA Rare Earth, Critical Metals and other rare earth associated names are higher between 5% and 10% heading into the cash open on Monday on the news.

At this point it's safe to say last week's Reuters rare earth hit piece (authored most likely at the behest of a disgruntled short), which sent the sector tumbling on disputed claims the Trump administration was seeking to distance itself from the rare earth space by moving away from a price floor on critical metals and suggesting MP's deal with the government may be in question, has been thoroughly debunkedEven the MP Materials X account was mocking the grotesque misreporting:

Project Vault will be financed through a mix of private and public funding: $1.67 billion is expected to come from private investors, while the US Export-Import Bank is set to provide a $10 billion loan with a 15-year term. The bank’s board is scheduled to vote on the deal, which would be the largest in its history.

More than a dozen major companies have joined Project Vault, including General Motors, Stellantis, Boeing, Corning, GE Vernova, and Google. Three large trading firms - Hartree Partners, Traxys North America, and Mercuria Energy - will handle sourcing and purchasing materials for the stockpile.

Some details about Project Vault’s structure were not immediately known, including the institutional investors providing the $1.67 billion (although JPMorgan will likely be among them). The senior administration officials said the project had been oversubscribed because investors are attracted by a credit-worthy group of manufacturers, their long-term commitments and the involvement of the US export-credit agency. 

The specific carrying costs that would be charged to those manufacturers, as well as the fees for the trading firms participating as procurement officers, weren’t disclosed.  Under the arrangement, companies that make an initial commitment to purchase materials at a specified inventory price later — and pay some up-front fees — will be able to present Project Vault with a shopping list of preferred materials they need. 

The project, in turn, will seek to procure and store the materials, with the manufacturers charged a carrying cost for the expenses associated with interest on the loan and holding the elements.  Manufacturers will be allowed to draw down their material stash as long as the firms replenish them. In the case of a major supply disruption, they will be able to access all of it, the officials said. 

Project Vault represents the first major public-private partnership under the Trump admin seeking reshoring of a critical supply chain, and blends government-backed financing with private investment and corporate participation. While the plan aims to strengthen domestic supply chains, it comes at a time when rare earth mining stocks such as MP Materials and USA Rare Earth are trading well below their recent highs.

Bloomberg writes that rather than focusing on oil, which naturally is at the basis of the nation’s emergency petroleum reserve, this new effort will concentrate on minerals such as gallium and cobalt.

These materials are used in a wide range of products, including smartphones, electric vehicle batteries, and aircraft engines. The stockpile is expected to cover both rare earth elements and other critical minerals whose prices tend to be unstable.

According to senior administration officials, the initiative would represent the first large-scale mineral reserve designed specifically for private-sector use

Investor interest has reportedly been strong, with officials saying the project is oversubscribed. They attribute this to the participation of major manufacturers, long-term purchasing commitments, and the backing of a federal credit agency. However, the identities of the main institutional investors and the exact cost structure have not yet been disclosed.

The program is part of a broader push to cut US reliance on China, which dominates much of the critical minerals supply chain. While the US maintains a reserve for defense needs, it has never created a similar system for civilian industries. The government has also expanded domestic investment and international cooperation with partners such as Australia, Japan, and Malaysia.

Momentum increased after China tightened export controls last year, forcing some US manufacturers to reduce output and exposing supply vulnerabilities. Under the system, companies will commit in advance to buy set quantities at agreed prices, pay upfront fees, and submit lists of needed materials, which Project Vault will acquire and store.

A central feature is price stabilization: firms must agree to repurchase the same volumes at the same prices in the future, a structure meant to limit volatility and protect against sudden cost spikes like the post-Ukraine surge in nickel prices. Trump is expected to discuss the plan with GM chief executive Mary Barra and mining entrepreneur Robert Friedland.

https://www.zerohedge.com/markets/trump-backs-critical-minerals-12b-stockpile-rare-earth-shares-jump


Sunday, February 1, 2026

FDA Action Alert: Sanofi/Regeneron, Merck, REGENXBIO and More

 

In what is shaping up to be a back-loaded month, the FDA is set to release a slew of regulatory decisions in February, including two that would expand the labels of blockbuster drugs.

REGENXBIO Readies for Hunter Decision After Delay

Kicking off the month is REGENXBIO, which by Feb. 8 is expecting the FDA’s verdict on its Hunter syndrome gene therapy RGX-121. The Maryland-based biotech had originally expected a decision on RGX-121 by Nov. 9, but the FDA extended the deadline by three months to allow time to review longer-term clinical data submitted by REGENXBIO.

Also known as mucopolysaccharidosis II, Hunter syndrome is a rare condition caused by mutations in the iduronate-2-sulfatase (IDS) gene, resulting in a dysfunctional enzyme that under healthy circumstances helps degrade waste inside the cell. The toxic buildup of cellular waste, in turn, leads to hallmark symptoms of Hunter syndrome, such as developmental delay and growth abnormalities.

RGX-121 delivers a functioning copy of the IDS gene and restores the body’s ability to produce healthy levels of the corresponding enzyme. Data from the Phase I/II/III CAMPSIITE study, released in February 2024, showed an 86% median reduction in DS26, a disease biomarker indicative of brain disease activity.

DS26 levels approached normal in the study, REGENXBIO said at the time.

RGX-121 has the potential to become the first one-time therapy that targets the underlying cause of Hunter syndrome, according to an August 2025 news release from the company.

Merck Looks to Expand Keytruda Into Ovarian Cancer

Merck is seeking to add another indication to the more than 40 for which its blockbuster cancer drug Keytruda is already approved.

By Feb. 20, the FDA is expected to release its decision on the proposed combination of the PD-1 inhibitor with chemotherapy, with or without Roche’s Avastin, for the treatment of platinum-resistant recurrent ovarian cancer.

To support its application, Merck submitted data from the Phase III KEYNOTE-B96 trial, which in October last year demonstrated a 30% improvement in progression-free survival versus placebo, and a 24% drop in the risk of death from all causes. Nearly all patients experienced toxicities related to the study’s investigational regimen, leading to death in 0.9% of patients. In comparison, 1.6% of placebo counterparts died due to side effects.

Keytruda has not yet been approved to treat any kind of ovarian cancer.

Vanda Awaits Verdict for Bysanti in Bipolar I, Schizophrenia

Vanda Pharmaceuticals is proposing its atypical antipsychotic Bysanti for the treatment of acute bipolar I disorder and schizophrenia. The FDA’s decision is expected on Feb. 21.

Bysanti’s active ingredient is milsaperidone, an active metabolite of iloperidone, which is also owned by Vanda and is approved under the brand name Fanapt for the same indications that Bysanti is targeting.

In a March 2025 news release, Vanda said that when taken orally, Bysanti converts to Fanapt and that the two drugs have been shown in clinical studies to be “bioequivalent at both low and high doses.” The company backed this claim with pharmacokinetic data showing comparable changes in levels over time between the two drugs.

Given this chemical similarity, Vanda is supporting Bysanti’s application with studies described in Fanapt’s label. The safety package for Bysanti will also include data from Fanapt’s clinical development as well as post-marketing experience with the drug, covering more than 80,000 patient-years of exposure.

Taiho Proposes Combo Regimen of Inqovi for Leukemia

Taiho Oncology is combining its cancer drug Inqovi with AbbVie and Roche’s BCL-2 inhibitor Venclexta for the treatment of acute myeloid leukemia (AML). A verdict is expected on Feb. 25.

Specifically, Taiho is proposing the combination in patients who are unable to undergo intensive induction chemotherapy. In the Phase IIb ASCERTAIN-V study, the investigational regimen elicited a complete response rate of 46.5%. Lowering the bar to include complete responders with incomplete hematologic recovery bumped this rate up to 63.4%, according to a May 2025 publication in the Journal of Clinical Oncology.

Inqovi combines two drugs: the nucleoside metabolic inhibitor decitabine and the cytidine deaminase inhibitor cedazuridine. The first chemical triggers the death of cancer cells, while the second increases the overall systemic exposure of decitabine. Inqovi was first approved by the FDA in July 2020 for the treatment of myelodysplastic syndromes.

If approved for this indication, Inqovi would become the first all-oral alternative to current AML therapies, Taiho CMO Harold Keer said in a July 2025 news release.

Eton Targets Diabetes Insipidus With Oral Solution

By Feb. 25, the FDA is expected to release its decision on Eton Pharmaceuticals’ ET-600, an oral desmopressin solution, for the treatment of diabetes insipidus.

Affecting 1 in 25,000 people worldwide, diabetes insipidus is a rare disease characterized by the over-production of urine. The condition develops when the body fails to make enough vasopressin, an antidiuretic hormone that helps maintain fluid balance in the body. Desmopressin is a synthetic form of vasopressin.

Pivotal data in March 2025 showed that ET-600 is bioequivalent to an FDA-approved reference product containing the same active ingredients. Compared to commercial products, however, ET-600, if approved, “can accommodate the precise and titratable doses necessary for pediatric patients,” CEO Sean Brynjelsen said at the time.

Following Delay, Ascendis Awaits Decision on Dwarfism Drug

Late last year, the FDA pushed back by three months its decision date for Ascendis Pharma’s investigational achrondroplasia drug TransCon CNP. That extension is nearing its end, with a verdict expected by Feb. 28.

While it qualifies as a rare disease—achondroplasia affects around 15,000 to 40,000 newborns—it is nevertheless the most common cause of dwarfism. The disease is caused by a gain-of-function mutation in the FGFR3 gene, which ultimately suppresses the activity of cells involved in bone development. A crucial player in this pathway is C-type natriuretic peptide, a hormone that counteracts FGFR3.

TransCon CNP works by mimicking the function of this hormone and helps spur bone growth in patients. In the Phase II ACcomplisH trial, treatment improved annualized growth velocity to 5.42 cm per year, as compared with 4.35 cm per year in placebo comparators. A 2023 publication in The Lancet noted that this treatment benefit was statistically significant.

If approved, TransCon CNP is expected to pose a substantial challenge to BioMarin’s achondroplasia medicine Voxzogo. In its third-quarter earnings call in October last year, BioMarin walked back its previously set revenue goal of $4 billion by 2027, with CFO Brian Mueller pointing specifically to the “impact of potential Voxzogo” competitors.

BioMarin Targets Younger PKU Population for Palynziq

Looking to broaden its patient population, BioMarin is seeking a label expansion for its enzyme substitution therapy Palynziq, with a target action date of Feb. 28.

Specifically, the California company is looking to lower the age of eligibility for the drug to include adolescents from 12 through 17 years with phenylketonuria (PKU). Palynziq is currently only indicated for adults who have uncontrolled blood phenylalanine levels.

Data from the Phase III PEGASUS study, released in September last year, showed that Palynziq treatment lowered blood phenylalanine levels by 49.7% on average at 72 weeks, as compared with dietary adjustments alone. Mean baseline phenylalanine was 1,026.4 µmol/L and nearly half of patients had concentrations above 1,000 µmol/L.

Nearly half of treated patients saw at least a 50% reduction in phenylalanine levels at 72 weeks, BioMarin added at the time.

PKU is a genetic disease that renders the phenylalanine hydroxylase enzyme dysfunctional, in turn disrupting the normal metabolism of phenylalanine, commonly found in many protein-containing foods. Patients with this condition suffer from the complications of phenylalanine buildup, such as seizures, tremors and intellectual disabilities.

Sanofi, Regeneron Eye Another Indication for Dupixent

Capping off this list is Sanofi and Regeneron’s blockbuster drug Dupixent, which the partners are proposing for the treatment of allergic fungal rhinosinusitis (AFRS). The FDA’s verdict is expected on Feb. 28.

AFRS is a distinct subtype of chronic rhinosinusitis characterized by an excessive inflammatory reaction at the sinuses, driven by a hypersensitivity to fungi. Patients often suffer from nasal congestion and thick mucus discharge, and the condition can lead to nasal polyps, poor quality of life and even bone deformation around the sinus cavities. Current treatments include surgery and a lengthy course of systemic steroids.

Sanofi and Regeneron are supporting their expansion bid with data form the Phase III LIBERTY-AFRS-AIMS study, which in November last year demonstrated a 50% improvement in nasal congestion at 52 weeks, as compared with 9.8% in placebo comparators. Dupixent likewise hit key secondary endpoints, including patient-reported nasal obstruction, nasal polyp size and the need for corticosteroids or surgery.

https://www.biospace.com/fda/fda-action-alert-sanofi-regeneron-merck-regenxbio-and-more

AstraZeneca lists on the NYSE on Monday, ending ADS program

 Pharma giant AstraZeneca (AZN) is transitioning its U.S. listing by delisting American Depositary Shares (ADS) from Nasdaq and directly listing its ordinary shares on the New York Stock Exchange (NYSE) starting Monday, February 2, 2026.

ADS and certain debt securities cease trading on the Nasdaq after market close on January 30, 2026. While the ordinary shares (AZN) and debt securities begin trading on the NYSE on February 2, 2026.

The shift simplifies AstraZeneca's (AZN) structure by replacing two-for-one ADS with direct $0.25 ordinary shares, enabling global investors to trade consistently across exchanges without ADS intermediaries.

At the same time, the pharma company is also investing billions in China and partnering with a Chinese biotech on weight-loss drugs. “These investments span the value chain, from drug discovery and clinical development to manufacturing, and bring Chinese innovation to the world,” the company said. 

https://www.msn.com/en-us/money/markets/astrazeneca-lists-on-the-nyse-on-monday-ending-ads-program/ar-AA1VsXAd

"Energy Suicide": Slovak PM Fico To Sue After Brussels Issues Total Ban On Russian Gas

 Via Remix News,

Slovakia is obliged to stop taking over Russian gas by Nov. 1, 2027, at the latest, and according to Slovak Prime Minister Robert Fico, the EU decision to ban all gas from member states amounts to “energy suicide.” As a result, Bratislava will file a lawsuit at the Court of Justice of the European Union (ECJ) against the newly adopted regulations.

On Monday, the Council of the European Union and the European Parliament formally adopted the new legislation on the gradual phase-out of Russian gas and oil imports. The move is part of the REPowerEU plan, which aims to become independent from Russian energy carriers.

Fico immediately criticized the move, calling it “energy suicide,” and said that “when the military conflict ends, everyone will be breaking their legs, rushing to go to Russia to do business.”

Fico announced that Slovakia will file a lawsuit against the adopted regulation at the Court of Justice of the European Union based in Luxembourg, writes Hlavnespravy.sk.

According to Fico, the country will argue that the regulation violates the principles of subsidiarity and proportionality.

He added that the Slovak Ministry of Justice, together with the portfolio responsible for foreign and European affairs, had prepared a “very professional document” and that they would be asking for the regulation to be declared contrary to the basic principles of the EU.

Fico also announced that Hungary, which voted against the legislation together with Slovakia, is also filing a lawsuit. It is not possible to file a joint action, but the argument is coordinated with the Hungarian side.

Fico says the war in Ukraine will be over by Nov. 1, 2027, “and everyone comes to their sense.” He believed that detaching from Russian energy in this way was suicide, and that not only he, but also German economists, politicians, and other EU politicians see it that way. According to his claim, the decision was made on a meaningless, ideological basis, due to hatred towards the Russian Federation.

Fico has long called for a ceasefire in the war, leading some to criticize his position in the conflict. However, his point about Russian energy has been echoed across the political spectrum in Europe, especially during a time when European nations feel threatened by the U.S.’s increasingly dominant position in supplying Europe’s energy needs. If the U.S. were to decide to curtail liquified natural gas (LNG) deliveries, for instance, it could be disastrous for Europe.

Fico also criticized the fact that the decree was adopted by a qualified majority. According to him, the European Commission has circumvented the principle of unanimity, which should be applied in the event of sanctions. The Slovak prime minister assessed this as a violation of the basic principles of the EU treaties. Increasingly, decisions on immigration, foreign policy, and a range of other issues are being taken by “qualified majority,” but since the EU cannot reach this, it is now violating the founding treaties to pass through its agenda.

He also warned that Slovakia could find itself in a situation where the energy carrier concerned would not be sufficient due to the regulation. As he puts it, “one dependency will be replaced by another”, and Europe will have to obtain even higher quantities of liquefied gas from the United States.

According to Fico, Slovakia has already suffered significant damage when the transit of Russian gas on the territory of the country stopped. According to him, this was caused by the decision of the Ukrainian president and meant a loss of up to €500 million per year due to the lack of transit fees.

As reported in Hungarian outlet Hirado.hu, the situation of European gas supply continues to deteriorate after the Arctic cold in the United States significantly reduced LNG production. Due to the extreme frosts, American gas production decreased by about 11 percent, and prices more than doubled, while domestic consumption increased sharply. There is fear that exports, including shipments to Europe, may also decline.

The European market is particularly vulnerable, as the filling of gas reservoirs has already fallen below 45 percent and is in danger of falling below 25 percent.

In Germany, reservoirs are already under 41 percent filled and incoming LNG is used immediately, which means that strategic reserves are barely formed. All of this means price increases are coming at a time when the EU is urging complete separation from Russian natural gas.

The development of the situation depends crucially on how long the extreme cold lasts in the United States and when LNG plants can return to normal operation.

https://www.zerohedge.com/geopolitical/energy-suicide-slovak-pm-fico-sue-after-brussels-issues-total-ban-russian-gas

San Francisco Ends $5M-A-Year Program That Supplied Alcohol To Homeless Addicts

 Sigh. It's not parody. It's San Francisco. The city is shutting down a controversial program that used millions in taxpayer funds to provide alcohol to homeless residents struggling with addiction, according to the NY Post.

Mayor Daniel Lurie said the city will end the Managed Alcohol Program, which cost about $5 million each year and began during the COVID-19 pandemic.

“For years, San Francisco was spending $5 million a year to provide alcohol to people who were struggling with homelessness and addiction — it doesn’t make sense, and we’re ending it,” Lurie told The California Post.

The program was launched in April 2020, when the city placed unhoused residents in hotels during lockdowns. Medical staff supplied controlled amounts of beer and liquor to prevent dangerous withdrawal symptoms while stores and bars were closed. Although intended as a temporary measure, it continued for nearly six years.

During its operation, the program served only 55 people, translating to an average cost of roughly $454,000 per client.

Now, Lurie says the city has fully pulled its support.

“We have ended every city contract for that program,” he said.

Community Forward, the nonprofit that managed the initiative in recent years, confirmed that the city has terminated its funding. Financial records show the group received millions in public money, much of it spent on staff salaries.

San Francisco’s program was the first of its kind in the United States, modeled loosely on similar efforts in Canada. Unlike other harm-reduction policies, such as needle exchanges, MAP directly supplied alcohol to people already dependent on it.

Since taking office last year, Lurie has moved away from long-standing harm-reduction policies. He has also ended the distribution of drug-use equipment and pushed for stricter enforcement of street drug activity.

“Under my administration, we made San Francisco a recovery-first city and ended the practice of handing out fentanyl smoking supplies so people couldn’t kill themselves on our streets,” Lurie said.

“We have work to do, but we have transformed the city’s response, and we are breaking the cycles of addiction, homelessness and government failure that have let down San Franciscans for too long.”

Last year, he warned open-air drug markets that enforcement would increase.

“If you do drugs on our streets, you will be arrested,” Lurie said. “And instead of sending you back out in crisis, we will give you a chance to stabilize and enter recovery.”

The Post writes that recovery advocates welcomed the decision to end MAP. Tom Wolf, a former homeless addict who now works in outreach, said the program wasted public funds.

“They [were] wasting our money just paying people to keep using the drug that they’re hopelessly addicted to,” Wolf said.

He also criticized how harm reduction has evolved.

“Harm reduction itself is part of the overall social justice framework,” he said, adding that it has shifted from preventing disease to “supporting drug users.”

Steve Adami, head of the Salvation Army’s recovery-focused program in San Francisco, said the city is now rethinking decades of policy.

“Under Mayor Lurie, they have reassessed the outcomes of those models,” Adami said. “That we are a recovery-first city. He’s made a significant investment into abstinence-based and recovery-focused services.”

In May, Lurie signed the Recovery First Act, signaling a shift toward abstinence and treatment-based approaches.

Despite the changes, major challenges remain. San Francisco has limited detox capacity, with only about 68 beds for thousands of people who cycle through homelessness each year. Many residents seeking help still face long waits for treatment.

The end of the alcohol program reflects the mayor’s broader effort to reverse years of permissive policies as he tries to address addiction, homelessness, and the decline of the city’s downtown core.

https://www.zerohedge.com/markets/san-francisco-ends-5m-year-program-supplied-alcohol-homeless-addicts